EZH2 Promotes T Follicular Helper Cell Differentiation Through Enhancing STAT3 Phosphorylation in Patients With Primary Sjögren's Syndrome.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 18 04 2022
accepted: 16 05 2022
entrez: 7 7 2022
pubmed: 8 7 2022
medline: 9 7 2022
Statut: epublish

Résumé

Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that plays an essential role in immune system development and autoimmune diseases. This study aimed to characterize the role of EZH2 in the pathogenesis of primary Sjögren's syndrome (pSS). We analyzed EZH2 expression in two transcriptomic datasets of peripheral blood mononuclear cells (PBMCs) from pSS patients and healthy controls. We measured EZH2 expression in CD4 EZH2 was upregulated in GSE164885 and GSE48378. EZH2 expression was higher in pSS CD4 EZH2 expression was abnormally elevated in pSS CD4

Identifiants

pubmed: 35795677
doi: 10.3389/fimmu.2022.922871
pmc: PMC9252457
doi:

Substances chimiques

STAT3 Transcription Factor 0
STAT3 protein, human 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

922871

Informations de copyright

Copyright © 2022 He, Yang, Chen, Liu, Lyu, Zeng, Wang, Li, Wang, Chen and Zhang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Arthritis Rheumatol. 2018 May;70(5):774-784
pubmed: 29361207
J Immunol. 2014 Jun 1;192(11):5012-22
pubmed: 24760151
EMBO Rep. 2017 Apr;18(4):619-631
pubmed: 28223321
Sci Rep. 2015 Jun 19;5:10643
pubmed: 26090605
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Expert Opin Ther Targets. 2019 Dec;23(12):1015-1030
pubmed: 31747802
Blood. 2014 Jul 31;124(5):737-49
pubmed: 24951427
J Autoimmun. 2018 Feb;87:16-25
pubmed: 29191572
Front Immunol. 2021 Mar 26;12:653989
pubmed: 33868295
J Exp Med. 2018 Mar 5;215(3):815-825
pubmed: 29378778
Nat Med. 2016 Feb;22(2):128-34
pubmed: 26845405
Cell Mol Immunol. 2020 Mar;17(3):247-260
pubmed: 30842630
Ann Rheum Dis. 2020 Dec;79(12):1588-1599
pubmed: 32963045
Clin Immunol. 2013 May;147(2):95-104
pubmed: 23578551
Immunity. 2008 Jul 18;29(1):138-49
pubmed: 18599325
Arthritis Rheumatol. 2017 Sep;69(9):1850-1861
pubmed: 28564491
J Biol Chem. 2008 May 9;283(19):13471-81
pubmed: 18285333
Clin Exp Immunol. 2012 Aug;169(2):89-99
pubmed: 22774983
J Immunol. 2017 Oct 1;199(7):2377-2387
pubmed: 28848064
Nat Rev Rheumatol. 2021 Jun;17(6):333-348
pubmed: 33911236
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1988-96
pubmed: 24966908
Arthritis Rheumatol. 2020 Jul;72(7):1143-1153
pubmed: 31961063
Blood. 2013 May 30;121(22):4512-20
pubmed: 23529930
Cancer Cell. 2013 Jun 10;23(6):839-52
pubmed: 23684459
Biochem Biophys Res Commun. 2012 Jun 1;422(2):238-44
pubmed: 22575453
Arthritis Rheumatol. 2018 Jan;70(1):98-108
pubmed: 28973837
Clin Rev Allergy Immunol. 2021 Feb;60(1):111-131
pubmed: 32390096
Front Immunol. 2018 Aug 15;9:1884
pubmed: 30158933
J Clin Invest. 2020 Nov 2;130(11):5765-5781
pubmed: 32701505
J Leukoc Biol. 2021 Jul;110(1):77-87
pubmed: 33040370
Nat Rev Rheumatol. 2019 Aug;15(8):475-490
pubmed: 31289377
Immunity. 2013 Nov 14;39(5):819-32
pubmed: 24238339
J Exp Med. 2018 May 7;215(5):1365-1382
pubmed: 29626115
Immunity. 2015 Feb 17;42(2):227-238
pubmed: 25680271
N Engl J Med. 2018 Mar 08;378(10):931-939
pubmed: 29514034
Immunity. 2014 Mar 20;40(3):367-77
pubmed: 24631156
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Biol Chem. 2020 Jul 28;401(8):933-943
pubmed: 32045348
Arthritis Res Ther. 2020 Jun 5;22(1):133
pubmed: 32503684
J Autoimmun. 2020 Mar;108:102404
pubmed: 31952907
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
J Rheumatol. 2017 Jan;44(1):49-58
pubmed: 28042126
Blood. 2012 Apr 26;119(17):3997-4008
pubmed: 22403255
Nat Rev Rheumatol. 2021 Aug;17(8):475-486
pubmed: 34188206
Nat Commun. 2018 Dec 21;9(1):5452
pubmed: 30575739

Auteurs

Chengmei He (C)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Yanlei Yang (Y)

Medical Science Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zhilei Chen (Z)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Suying Liu (S)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Taibiao Lyu (T)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Liuting Zeng (L)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Li Wang (L)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Yongzhe Li (Y)

Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Mu Wang (M)

Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Hua Chen (H)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Fengchun Zhang (F)

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH